![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
SpikoGen features the SARS-CoV-2 spike protein and Vaxine’s own Advax-SM adjuvant. The placebo-controlled SpikoGen trial has coprimary endpoints investigating the occurrence of symptomatic Covid-19 and severe Covid-19, with both endpoints.
Lead Product(s): SARS-CoV-2 Recombinant Spike Protein,Advax-SM
Therapeutic Area: Infections and Infectious Diseases Product Name: SpikoGen
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Vaxine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2021